World J Mens Health.  2014 Apr;32(1):18-27.

Mirodenafil for the Treatment of Erectile Dysfunction: A Systematic Review of the Literature

• Park HJ
• Moon KH
• Lee SW
• Lee WK
• Kam SC
• Lee JH
• Park NC

Abstract

Phosphodiesterase type 5 (PDE5) inhibitors are the most commonly used treatment for erectile dysfunction (ED). Since the launch of sildenafil, several drugs-including mirodenafil, sildenafil citrate (sildenafil), tadalafil, vardenafil HCL (vardenafil), udenafil, and avanafil-have become available. Mirodenafil is a newly developed pyrrolopyrimidinone compound, which is a potent, reversible, and selective oral PDE5 inhibitor. Mirodenafil was launched in Korea in 2007, and an orally disintegrating film of mirodenafil was developed in 2011 for benefitting patients having difficulty in swallowing tablets. This study aimed to review the pharmacokinetic characteristic profile of mirodenafil and report evidence on its efficacy in the case of ED. In addition, we reviewed randomized controlled studies of mirodenafil's daily administration and efficacy for lower urinary tract symptoms.

Keyword

Erectile dysfunction; Phosphodiesterase 5 inhibitors; Review; Treatment efficacy

MeSH Terms

Citric Acid
Deglutition
Erectile Dysfunction*
Humans
Korea
Lower Urinary Tract Symptoms
Male
Phosphodiesterase 5 Inhibitors
Tablets
Treatment Outcome
Sildenafil Citrate
Tadalafil
Vardenafil Dihydrochloride
Citric Acid
Phosphodiesterase 5 Inhibitors
Tablets

Reference

1. Paick JS, Ahn TY, Choi HK, Chung WS, Kim JJ, Kim SC, et al. Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J Sex Med. 2008; 5:2672–2680.

2. Paick JS, Choi HK, Kim SC, Ahn TY, Kim JJ, Park JK, et al. Efficacy and safety of oral SK3530 for the treatment of erectile dysfunction in Korean men: a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group clinical trial. Asian J Androl. 2008; 10:791–798.

3. Lee J, Yoo HH, Rhim KJ, Sohn DR, Kim DH. Metabolism and excretion of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo [3,2-d]-pyrimidin-4-one (SK3530) in rats. Rapid Commun Mass Spectrom. 2007; 21:1139–1149.

4. Oh JG, Jang WJ, Chi SC. Validation of a HPLC method for the quantification and purity determination of SK3530 in drug substance and tablet. J Pharm Biomed Anal. 2007; 43:1179–1184.

5. Yoo HH, Kim NS, Im GJ, Kim DH. Pharmacokinetics and tissue distribution of a novel PDE5 inhibitor, SK-3530, in rats. Acta Pharmacol Sin. 2007; 28:1247–1253.

6. Lee SK, Kim Y, Kim TK, Im GJ, Lee BY, Kim DH, et al. Determination of mirodenafil and sildenafil in the plasma and corpus cavernous of SD male rats. J Pharm Biomed Anal. 2009; 49:513–518.

7. Shin BS, Hu SK, Kim J, Oh JG, Youn WN, Lee B, et al. Development of LC/MS/MS assay for the determination of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one (SK3530) in human plasma: application to a clinical pharmacokinetic study. J Pharm Biomed Anal. 2007; 45:176–184.

8. Choi YH, Lee YS, Bae SH, Kim TK, Lee BY, Lee MG. Dose-dependent pharmacokinetics and first-pass effects of mirodenafil, a new erectogenic, in rats. Biopharm Drug Dispos. 2009; 30:305–317.

9. Lee HS, Park EJ, Ji HY, Kim SY, Im GJ, Lee SM, et al. Identification of cytochrome P450 enzymes responsible for N-dealkylation of a new oral erectogenic, mirodenafil. Xenobiotica. 2008; 38:21–33.

10. Kim JJ, Han DH, Lim SH, Kim TH, Chae MR, Chung KJ, et al. Effects of Ginkgo biloba extracts with mirodenafil on the relaxation of corpus cavernosal smooth muscle and the potassium channel activity of corporal smooth muscle cells. Asian J Androl. 2011; 13:742–746.

11. Jung JY, Kim SK, Kim BS, Lee SH, Park YS, Kim SJ, et al. The penile erection efficacy of a new phosphodiesterase type 5 inhibitor, mirodenafil (SK3530), in rabbits with acute spinal cord injury. J Vet Med Sci. 2008; 70:1199–1204.

12. Park K, Ryu KS, Li WJ, Kim SW, Paick JS. Chronic treatment with a type 5 phosphodiesterase inhibitor suppresses apoptosis of corporal smooth muscle by potentiating Akt signalling in a rat model of diabetic erectile dysfunction. Eur Urol. 2008; 53:1282–1288.

13. Kim H, Sohn DW, Kim SD, Hong SH, Suh HJ, Lee CB, et al. The effect of mirodenafil on the penile erection and corpus cavernosum in the rat model of cavernosal nerve injury. Int J Impot Res. 2010; 22:291–297.

14. Porst H. IC351 (tadalafil, Cialis): update on clinical experience. Int J Impot Res. 2002; 14:Suppl 1. S57–S64.

15. Shin KH, Kim BH, Kim TE, Kim JW, Yi S, Yoon SH, et al. The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study. Clin Ther. 2009; 31:3009–3020.

16. Klotz T, Sachse R, Heidrich A, Jockenhövel F, Rohde G, Wensing G, et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol. 2001; 19:32–39.

17. Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract. 2002; 56:453–459.

18. Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol. 2002; 53:Suppl 1. 5S–12S.

19. Wright PJ. Comparison of phosphodiesterase type 5 (PDE5) inhibitors. Int J Clin Pract. 2006; 60:967–975.

20. Kim BH, Yi S, Kim J, Lim KS, Kim KP, Lee B, et al. Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea. Clin Ther. 2009; 31:1234–1243.

21. Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med. 2003; 139:161–168.

22. Porst H, Young JM, Schmidt AC, Buvat J. International Vardenafil Study Group. Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroups. Urology. 2003; 62:519–523.

23. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998; 338:1397–1404.

24. Padma-Nathan H, McMurray JG, Pullman WE, Whitaker JS, Saoud JB, Ferguson KM, et al. On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Int J Impot Res. 2001; 13:2–9.

25. Yuan J, Zhang R, Yang Z, Lee J, Liu Y, Tian J, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol. 2013; 63:902–912.

26. Shamloul R, Ghanem H. Erectile dysfunction. Lancet. 2013; 381:153–165.

27. Vardi M, Nini A. Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. Cochrane Database Syst Rev. 2007; (1):CD002187.

28. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol. 2003; 92:47M–57M.

29. van Ahlen H, Wahle K, Kupper W, Yassin A, Reblin T, Neureither M. Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. J Sex Med. 2005; 2:856–864.

30. Lombardi G, Nelli F, Celso M, Mencarini M, Del Popolo G. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature. J Sex Med. 2012; 9:970–985.

31. Lee YS, Choi YH, Kim TK, Ryu KH, Lee BY, Lee MG. Pharmacokinetics of mirodenafil and its two metabolites, SK3541 and SK3544, after intravenous and oral administration of mirodenafil to streptozotocin-induced diabetes mellitus rats. Xenobiotica. 2010; 40:129–137.

32. Park HJ, Choi HK, Ahn TY, Park JK, Chung WS, Lee SW, et al. Efficacy and safety of oral mirodenafil in the treatment of erectile dysfunction in diabetic men in Korea: a multicenter, randomized, double-blind, placebo-controlled clinical trial. J Sex Med. 2010; 7:2842–2850.

33. Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. J Sex Med. 2009; 6:1232–1247.

34. Lee YS, Choi YH, Yoon IS, Kim TK, Ryu KH, Lee BY, et al. Pharmacokinetics of mirodenafil and its two metabolites, SK3541 and SK3544, in spontaneously or DOCA-salt-induced hypertensive rats. Biopharm Drug Dispos. 2011; 32:38–49.

35. Lee JH, Chae MR, Park JK, Jeon JH, Lee SW. The effects of the combined use of a PDE5 inhibitor and medications for hypertension, lower urinary tract symptoms and dyslipidemia on corporal tissue tone. Int J Impot Res. 2012; 24:221–227.

36. Paick JS, Kim JJ, Kim SC, Moon KH, Min KS, Park K, et al. Efficacy and safety of mirodenafil in men taking antihypertensive medications. J Sex Med. 2010; 7:3143–3152.

37. Lee WK, Lee SH, Cho ST, Lee YS, Oh CY, Yoo C, et al. Comparison between on-demand dosing of dapoxetine alone and dapoxetine plus mirodenafil in patients with life-long premature ejaculation: prospective, randomized, double-blind, placebo-controlled, multicenter study. J Sex Med. 2013; 10:2832–2841.

38. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002; 168:1332–1336.

39. Althof SE, Rubio-Aurioles E, Kingsberg S, Zeigler H, Wong DG, Burns P. Impact of tadalafil once daily in men with erectile dysfunction--including a report of the partners' evaluation. Urology. 2010; 75:1358–1363.

40. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2007; 177:1401–1407.

41. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol. 2008; 180:1228–1234.

42. Chung JH, Kang DH, Oh CY, Chung JM, Lee KS, Kim TH, et al. Safety and efficacy of once daily administration of 50 mg mirodenafil in patients with erectile dysfunction: a multicenter, double-blind, placebo controlled trial. J Urol. 2013; 189:1006–1013.

43. Eardley I, Dean J, Barnes T, Kirby M, Glasser D, Solanki J. The sexual habits of British men and women over 40 years old. BJU Int. 2004; 93:563–567.

44. Fisher WA, Rosen RC, Eardley I, Sand M, Goldstein I. Sexual experience of female partners of men with erectile dysfunction: the female experience of men's attitudes to life events and sexuality (FEMALES) study. J Sex Med. 2005; 2:675–684.

45. Hanson-Divers C, Jackson SE, Lue TF, Crawford SY, Rosen RC. Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol. 1998; 159:1541–1547.

46. Porst H, Giuliano F, Glina S, Ralph D, Casabé AR, Elion-Mboussa A, et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol. 2006; 50:351–359.

47. Konstantinopoulos A, Giannitsas K, Athanasopoulos A, Spathas D, Perimenis P. The impact of daily sildenafil on levels of soluble molecular markers of endothelial function in plasma in patients with erectile dysfunction. Expert Opin Pharmacother. 2009; 10:155–160.

48. Zhao C, Kim SW, Yang DY, Kim JJ, Park NC, Lee SW, et al. Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol. 2011; 60:380–387.

49. Zhao C, Kim SH, Lee SW, Jeon JH, Kang KK, Choi SB, et al. Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int. 2011; 107:1943–1947.

50. Zhanel GG, Craig WA. Pharmacokinetic contributions to postantibiotic effects. Focus on aminoglycosides. Clin Pharmacokinet. 1994; 27:377–392.

51. Borin MT, Hughes GS, Patel RK, Royer ME, Cathcart KS. Pharmacokinetic and tolerance studies of cefpodoxime after single- and multiple-dose oral administration of cefpodoxime proxetil. J Clin Pharmacol. 1991; 31:1137–1145.

52. Mostafa T. Oral phosphodiesterase type 5 inhibitors: nonerectogenic beneficial uses. J Sex Med. 2008; 5:2502–2518.

53. Broderick GA, Brock GB, Roehrborn CG, Watts SD, Elion-Mboussa A, Viktrup L. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. Urology. 2010; 75:1452–1458.

54. Lee JY, Cho SY, Oh CY, Ha US, Lee SH, Park SY, et al. Efficacy and safety of combination therapy with mirodenafil and α1-blocker for benign prostatic hyperplasia-induced lower urinary tract symptoms accompanied by erectile dysfunction: a multicenter, open-label, prospective study. Int J Impot Res. 2011; 23:249–256.

55. Bang WJ, Oh CY, Yoo C, Cho JS, Yang DY, Lee DH, et al. Efficacy and safety of the simultaneous administration of mirodenafil and an α-blocker in men with BPH-LUTS: a multicenter open-label prospective study. Int J Impot Res. 2013; 25:149–154.